NUVB
Nuvation Bio Inc.Marquee-fund ownership over time
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Greenlight Capital re-entered | Q2 2021 | 21Q | $0.00 | $4.21 | — |
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $2.83 | $4.21 | +49% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $4.21 | — |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $2.74 | $4.21 | +54% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $2.74 | $4.21 | +54% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $2.74 | $4.21 | +54% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $2.74 | $4.21 | +54% |
| Duquesne Family Office | Q2 2026 | 1Q | $4.32 | $4.21 | -3% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q1 2026 | Q2 2026 | → $4.32 | -27% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Nuvation Bio Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 26, 2026 — the most recent Form 4 on file — not from today.
- Form 40001369091-26-000003May 26, 2026
- Form 40002007102-26-000002May 26, 2026
- Form 40001206977-26-000006May 26, 2026
- Form 40001238913-26-000002May 26, 2026
- Form 40001620152-26-000003May 26, 2026
- Form 40001487815-26-000007May 26, 2026
- Form 4/Aamend0001487815-26-000006May 26, 2026
- Form 40001369453-26-000006Apr 21, 2026
- Form 40001937915-26-000004Apr 21, 2026
- Form 40001369453-26-000005Apr 8, 2026
- Form 40001937915-26-000003Mar 3, 2026
- Form 40002001938-26-000004Mar 3, 2026
- Form 40001369453-26-000003Mar 3, 2026
- Form 40002017751-26-000003Mar 3, 2026
- Form 40002039891-26-000003Mar 3, 2026
Fundamentals
XBRL · Nuvation Bio Inc.Annual figures sourced directly from Nuvation Bio Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Nuvation Bio Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 27, 2026
- 8-KMaterial eventMay 4, 2026
- 10-QQuarterly reportMay 4, 2026
- DEF 14AProxy statementApr 10, 2026
- 10-KAnnual reportMar 2, 2026
- 8-KMaterial eventMar 2, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventNov 26, 2025
- 8-KMaterial eventNov 17, 2025
- 10-QQuarterly reportNov 3, 2025
- 8-KMaterial eventNov 3, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
- 8-KMaterial eventJun 11, 2025
- 8-KMaterial eventMay 23, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Duquesne Family Office | Q2 2026 | open | $4.32 | $4.21 | -3% |
| Renaissance Technologies | Q2 2026 | open | $4.72 | $4.21 | -11% |
| D.E. Shaw | Q1 2026 | open | $5.88 | $4.21 | -28% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $5.88 | $4.32 | -27% |
| Point72 Asset Management | Q4 2024 | Q2 2025 | $2.87 | $2.24 | -22% |
| Citadel Advisors | Q3 2024 | Q2 2026 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $2.74 | $4.21 | +54% |
| Two Sigma Investments | Q3 2024 | open | $2.74 | $4.21 | +54% |
| D.E. Shaw | Q3 2024 | Q3 2025 | $2.74 | $2.76 | +1% |
| AQR Capital Management | Q3 2024 | open | $2.74 | $4.21 | +54% |
| Millennium Management | Q3 2024 | open | $2.74 | $4.21 | +54% |
| Renaissance Technologies | Q3 2024 | Q4 2025 | $2.83 | $4.69 | +66% |
| Greenlight Capital | Q2 2021 | open | $0.00 | — | +0% |
| Greenlight Capital | Q2 2021 | open | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.